Mr J. Van Roey, Tibotec
Mr J. Van Roey, Tibotec
Mr J. Van Roey, Tibotec
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Time to culture conversion (MGIT) on ITT<br />
population (n=44)<br />
Mean (±(<br />
SD) log 10 CFU count (SSCC)<br />
p = 0.003<br />
(a) p-value from Cox proportional model adjusting for strata<br />
33<br />
34<br />
Conclusions<br />
• MIC: 0.03µg/ml<br />
• No cross-resistance resistance with existing TB drugs<br />
• Potential for treatment shortening<br />
• Sterilizing activity in mouse model<br />
• In patients : EBA limited activity, good activity<br />
in phase II<br />
BACK-UP SLIDES<br />
35<br />
36<br />
New MDR-TB drugs – Jens <strong>Van</strong> <strong>Roey</strong>
Change language